Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07441408) titled 'Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Pulmonary Fibrosis
Intervention:
Drug: BMS-986278
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 16, 2026
Target Sample Size: 2277
Countries of Recruitment:
Argentina
Australia
Belgium
Chile
Colombia
Denmark
Finland
France
Ireland
M...